Literature DB >> 8670327

Reactive arthritis in patients attending an urban sexually transmitted diseases clinic.

E Rich1, E W Hook, G S Alarcón, L W Moreland.   

Abstract

OBJECTIVE: To assess the prevalence, clinical manifestations, associated genital infections, and HLA associations of reactive arthritis (ReA) among patients attending an urban sexually transmitted diseases (STD) clinic.
METHODS: Using a standardized questionnaire, 271 consecutive adults, primarily black, with possible or proven Chlamydia trachomatis genital infection were screened for symptoms of ReA. A followup questionnaire was administered 6 weeks later by mail. Patients who reported at least 1 symptom were evaluated by a rheumatologist. HLA-B typing was performed on patients with objective ReA features.
RESULTS: Nine of 217 patients (4.1%) with genital infection/inflammation had objective ReA features. Chlamydial or nongonococcal STD syndromes were diagnosed in 8 of these 9 patients (88%). Genital infection/inflammation was asymptomatic in 78% of patients with ReA features. HLA-B27 or other B7-cross-reactive group antigens were not associated with the occurrence of ReA.
CONCLUSION: Nongonococcal genital infections, often asymptomatic, can trigger a relatively mild ReA in a larger number of exposed patients than previously thought, irrespective of the individual's HLA status.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8670327     DOI: 10.1002/art.1780390715

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  15 in total

1.  Male sex predominance in Chlamydia trachomatis sexually acquired reactive arthritis: are women more protected by anti-chlamydia antibodies?

Authors:  S Bas; C Scieux; T L Vischer
Journal:  Ann Rheum Dis       Date:  2001-06       Impact factor: 19.103

Review 2.  HLA-B27-associated reactive arthritis: pathogenetic and clinical considerations.

Authors:  Inés Colmegna; Raquel Cuchacovich; Luis R Espinoza
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

3.  Frequency of triggering bacteria in patients with reactive arthritis and undifferentiated oligoarthritis and the relative importance of the tests used for diagnosis.

Authors:  C Fendler; S Laitko; H Sörensen; C Gripenberg-Lerche; A Groh; J Uksila; K Granfors; J Braun; J Sieper
Journal:  Ann Rheum Dis       Date:  2001-04       Impact factor: 19.103

Review 4.  The incidence of sexually acquired reactive arthritis: a systematic literature review.

Authors:  Hayley J Denison; Elizabeth M Curtis; Michael A Clynes; Collette Bromhead; Elaine M Dennison; Rebecca Grainger
Journal:  Clin Rheumatol       Date:  2016-08-01       Impact factor: 2.980

Review 5.  Chlamydia-Induced Reactive Arthritis: Disappearing Entity or Lack of Research?

Authors:  Henning Zeidler; Alan P Hudson
Journal:  Curr Rheumatol Rep       Date:  2019-11-19       Impact factor: 4.592

Review 6.  Chlamydia-induced ReA: immune imbalances and persistent pathogens.

Authors:  Eric Gracey; Robert D Inman
Journal:  Nat Rev Rheumatol       Date:  2011-11-22       Impact factor: 20.543

7.  Treating reactive arthritis: insights for the clinician.

Authors:  John D Carter
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-02       Impact factor: 5.346

8.  Randomised, blinded, placebo controlled trial of doxycycline for chronic seronegative arthritis.

Authors:  M Smieja; D W MacPherson; W Kean; M L Schmuck; C H Goldsmith; W Buchanan; L E Hart; J B Mahony
Journal:  Ann Rheum Dis       Date:  2001-12       Impact factor: 19.103

9.  The molecular basis for disease phenotype in chronic Chlamydia-induced arthritis.

Authors:  John D Carter; Herve C Gerard; Judith A Whittum-Hudson; Alan P Hudson
Journal:  Int J Clin Rheumtol       Date:  2012-12-01

10.  Chlamydiae as etiologic agents in chronic undifferentiated spondylarthritis.

Authors:  John D Carter; Hervé C Gérard; Luis R Espinoza; Louis R Ricca; Joanne Valeriano; Jessica Snelgrove; Cynthia Oszust; Frank B Vasey; Alan P Hudson
Journal:  Arthritis Rheum       Date:  2009-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.